QUOTE AND NEWS
Motley Fool  Dec 11  Comment 
Achillion Pharmaceuticals is conducting a study that could reduce hepatitis C treatment to six weeks.
Benzinga  Nov 13  Comment 
Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) gained nearly 19 percent Wednesday, mystifying a Deutsche Bank analyst. About 19.7 million shares changed hands Wednesday, vs. Achillion's average daily volume of 5.9 million shares. Achillion...
TheStreet.com  Nov 12  Comment 
NEW YORK (TheStreet) -- Shares of Achillion Pharmaceuticals  continued to climb, up 7.07% to $13.36, in late morning trading Wednesday after the company reported encouraging interim results from a Phase II study of its hepatitis C drug...
Motley Fool  Nov 12  Comment 
Achillion Pharmaceuticals is working on an adjunct therapy that could significantly reduce the number of weeks hepatitis C patients would require treatment.
Benzinga  Nov 10  Comment 
Midway through trading Monday, the Dow traded up 0.15 percent to 17,600.00 while the NASDAQ surged 0.26 percent to 4,644.54. The S&P also rose, gaining 0.20 percent to 2,036.02. Leading and Lagging Sectors Healthcare shares jumped by 0.71...
StreetInsider.com  Nov 10  Comment 
S&W Seed (Nasdaq: SANW) 31.8% HIGHER;Putnam Investments lowered its stake in the company from 1,169,834 shares to 309,375 shares, or 2.7 percent of total outstanding common. Orexigen Therapeutics (Nasdaq: OREX) 28.3% HIGHER; reported Q3 EPS of...
Benzinga  Nov 10  Comment 
Vimicro International (NASDAQ: VIMC) shares rose 10.38% to $10 in pre-market trading after gaining 1.91% on Friday. China Finance Online Co (NASDAQ: JRJC) shares gained 8.35% to $5.97 in the pre-market trading session after dropping 3.67% on...
StreetInsider.com  Nov 10  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Achillion+Pharma+%28ACHN%29+Reports+100%25+SVR12+in+a+Phase+2+Study+With+ACH-3102+at+AASLD/9992458.html for the full story.
newratings.com  Nov 8  Comment 
NEW YORK CITY (dpa-AFX) - Achillion Pharmaceuticals, Inc. (ACHN) Saturday said it achieved the primary obejective for its ongoing Phase 2 trial evaluating ACH-3102 in combination with sofosbuvir, for genotype 1 treatment HCV. In a late breaker...





You may also be interested in articles related to Achillion Pharmaceuticals (ACHN):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki